Walleye Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$14.9M Buy
28,500
+25,700
+918% +$13.2M 0.01% 956
2026
Q2
$1.39M Sell
2,800
-7,100
-72% -$3.15M 0.01% 1840
2026
Q1
$4.42M Sell
9,900
-4,700
-32% -$2.19M 0.02% 878
2025
Q4
$6.62M Buy
14,600
+14,000
+2,333% +$6.03M 0.02% 936
2025
Q3
$235K Sell
600
-8,700
-94% -$3.64M ﹤0.01% 3209
2025
Q2
$4.14M Sell
9,300
-1,100
-11% -$507K 0.02% 994
2025
Q1
$5.04M Buy
10,400
+4,400
+73% +$2.05M 0.02% 779
2024
Q4
$2.42M Sell
6,000
-6,800
-53% -$3.15M 0.01% 1610
2024
Q3
$5.95M Sell
12,800
-5,900
-32% -$2.83M 0.01% 1049
2024
Q2
$8.77M Sell
18,700
-22,800
-55% -$9.9M 0.02% 857
2024
Q1
$17.3M Buy
41,500
+31,900
+332% +$13.5M 0.03% 501
2023
Q4
$3.91M Sell
9,600
-44,800
-82% -$16.5M 0.01% 1261
2023
Q3
$18.9M Buy
54,400
+50,400
+1,260% +$17.6M 0.05% 282
2023
Q2
$1.41M Sell
4,000
-2,400
-38% -$809K 0.01% 1571
2023
Q1
$2.02M Buy
6,400
+600
+10% +$180K 0.03% 718
2022
Q4
$1.67M Buy
5,800
+200
+4% +$61K 0.03% 679
2022
Q3
$1.62M Buy
+5,600
New +$1.61M 0.03% 670
2020
Q2
– Sell
-1,900
Closed -$452K – 985
2020
Q1
$452K Sell
1,900
-11,500
-86% -$2.64M 0.1% 250
2019
Q4
$2.93M Buy
13,400
+3,700
+38% +$749K 0.19% 122
2019
Q3
$1.64M Buy
9,700
+2,700
+39% +$478K 0.1% 271
2019
Q2
$1.28M Buy
7,000
+6,200
+775% +$1.08M 0.14% 196
2019
Q1
$147K Buy
+800
New +$148K 0.02% 894

Other funds holding VRTX

Walleye Capital's VRTX Position: Q3 2026 in Review

Walleye Capital increased its Vertex Pharmaceuticals (VRTX) stake by 2,726% in Q3 2026, buying an estimated $4.68M and bringing the position to 9,466 shares worth $4.95M. The position accounts for ﹤0.01% of the portfolio, ranked #1902.

Walleye Capital first reported a position in VRTX in Q1 2019 and has held it in 28 quarters since. The position peaked at $19.4M in Q3 2022. 1,782 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • Walleye Capital held 9,466 shares of Vertex Pharmaceuticals worth $4.95M as of Q3 2026.
  • Walleye Capital bought 9,131 Vertex Pharmaceuticals shares in Q3 2026, an estimated $4.68M.
  • Vertex Pharmaceuticals made up ﹤0.01% of Walleye Capital's portfolio in Q3 2026, its #1902 holding.
  • Walleye Capital first reported a position in Vertex Pharmaceuticals in Q1 2019 and has held it in 28 quarters since.
  • Walleye Capital's Vertex Pharmaceuticals position peaked at $19.4M in Q3 2022.
  • 1,782 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Walleye Capital's 13F filing for Q3 2026, filed 13 Nov 2026.